2009 Webcasts
- "Schizophrenia as a Developmental Disorder: Implications for Prevention and Treatment"
View Grand Rounds
Neil Richtand, MD, PhD
Department of Psychiatry, University of Cincinnati
Originally aired on November 11, 2009
To complete the evaluation and post-test, a link is embedded in the video's "links" section. It is marked with a double paperclip.
- Planning committee member Drew Barzman, MD, receives research support from AstraZenca and Pfizer; is on the speaker's bureau for AstraZenca and provides CME programs for AstraZenca, Bristol-Myers, Squibb Company and Ostuka America Pharmaceutical, Inc. Dr. Richtand is a consultant for Forest Pharmaceuticals, Bristol-Myers Squibb and Gerson Lehrman Group. Dr. Richtand receives research support from Janssen, Astra-Zeneca, Dept of Veterans Affairs, NIH and NARSAD. Dr. Richtand receives honorarias from Bristol-Myers Squibb, Dimedix/Scius, Otsuka America Pharmaceutical and Schering-Plough.
- *All planning committee members'/faculty/faculty identified conflicts of interest pertaining to this activity were resolved prior to the activity.
Commercial support: AstraZenca
- "Treatment of Atypical Antipsychotic-Induced Obesity with Metformin"
View Grand Rounds
David Klein, MD
Division of Endocrinology, Cincinnati Children's
Originally aired on October 14, 2009
To complete the evaluation and post-test, a link is embedded in the video's "links" section. It is marked with a double paperclip.
- Planning committee member Drew Barzman, MD, receives research support from AstraZenca and Pfizer; is on the speaker's bureau for AstraZenca and provides CME programs for AstraZenca, Bristol-Myers, Squibb Company and Ostuka America Pharmaceutical, Inc
- *All planning committee members'/faculty/faculty identified conflicts of interest pertaining to this activity were resolved prior to the activity.
Commercial support: AstraZenca
- "Off-Label" Pharmacotherapy and Malpractice Liability: Avoiding Problems"
View Grand Rounds
Douglas Mossman, MD
Director, Glenn M. Weaver Institute of Law and Psychiatry - University of Cincinnati College of Law
Originally aired on September 9, 2009
To complete the evaluation and post-test, a link is embedded in the video's "links" section. It is marked with a double paperclip.
- Planning committee member Drew Barzman, MD, receives research support from AstraZenca and Pfizer; is on the speaker's bureau for AstraZenca and provides CME programs for AstraZenca, Bristol-Myers, Squibb Company and Ostuka America Pharmaceutical, Inc
- *All planning committee members'/faculty/faculty identified conflicts of interest pertaining to this activity were resolved prior to the activity.
Commercial support: AstraZenca
- *This presentation is approved for Social Work credit.
Cincinnati Children's Hospital Medical Center Social Service is an approved provider of social work clock hours by the State of Ohio Counselor, Social Worker, and Marriage and Family Therapist Board (provider number RSX069302). 1.0 Social Work CEUs offered.
- "Pediatric Bipolar Disorder: Phenomenology and Longitudinal Cause"
High Speed (Broadband)
David Axelson, MD
Associate Professor, Department of Psychiatry - University of Pittsburgh
Originally aired on May 13, 2009
Take the post-test for CME credit
- *Planning committee member Drew Barzman, MD, receives research support from AstraZenca and Pfizer; is on the speaker's bureau for AstraZenca and provides CME programs for AstraZenca, Bristol-Myers, Squibb Company and Ostuka America Pharmaceutical, Inc
- *All planning committee members'/faculty/faculty identified conflicts of interest pertaining to this activity were resolved prior to the activity.
Commercial support: AstraZenca
- "Controversies in the treatment of ADHD in Children and Adolescents"
High Speed (Broadband)
Steven R. Pliszka, MD
Chief, Division of Child and Adolescent Psychiatry - University of Texas Health Science Center at San Antonio
Originally aired on April 8, 2009
Take the post-test for CME credit
- *Speaker indicated the following: receives Grant/Research support from Ortho McNeil
- *Planning committee member Drew Barzman, MD, receives research support from AstraZenca and Pfizer; is on the speaker's bureau for AstraZenca and provides CME programs for AstraZenca, Bristol-Myers, Squibb Company and Ostuka America Pharmaceutical, Inc
- *All planning committee members'/faculty/faculty identified conflicts of interest pertaining to this activity were resolved prior to the activity.
Commercial support: AstraZeneca
- "School-Based Mental Health"
High Speed (Broadband)
Velissarios Karacostas, MD, PhD
Originally aired on March 11, 2009
Take the post-test for CME credit
- *Planning committee member Drew Barzman, MD, receives research support from AstraZenca and Pfizer; is on the speaker's bureau for AstraZenca and provides CME programs for AstraZenca, Bristol-Myers, Squibb Company and Ostuka America Pharmaceutical, Inc
- *All planning committee members'/faculty/faculty identified conflicts of interest pertaining to this activity were resolved prior to the activity.
Commercial support: AstraZenca
- "Understanding Juvenile Justice: Competency to Stand Trial"
High Speed (Broadband)
Paul A. Deardorff, PhD, ABPP
Originally aired on January 14, 2009
Take the post-test for CME credit
- *Planning committee member Drew Barzman, MD, receives research support from AstraZenca and Pfizer; is on the speaker's bureau for AstraZenca and provides CME programs for AstraZenca, Bristol-Myers, Squibb Company and Ostuka America Pharmaceutical, Inc
- *All planning committee members'/faculty/faculty identified conflicts of interest pertaining to this activity were resolved prior to the activity.
Commercial support: AstraZenca
2008 Webcasts
- "Managing Patients with Chronic Somatic Complaints"
High Speed (Broadband)
Sergio Delgado, MD
Originally aired on December 10, 2008
Take the post-test for CME credit
- Speaker indicated the following: is on the Speaker's Bureau for McNeil *All planning committee members'/faculty/faculty identified conflicts of interest pertaining to this activity were resolved prior to the activity.
Commercial support: AstraZeneca
- "Is Omega-3 Fatty Acid Deficiency a Preventable Neurodevelopmental Risk Factor for Psychiatric Disorders?"
High Speed (Broadband)
Robert McNamara, PhD
Originally aired on November 12, 2008
- Speaker indicated the following: Receives Grant/Research Support and is a Consultant for Martek Bioscience. *All planning committee members'/faculty/faculty identified conflicts of interest pertaining to this activity were resolved prior to the activity.
Commercial support: AstraZeneca
- "The Magic of ADHD Diagnosis: Trapping the Illusion"
High Speed (Broadband)
L. Eugene Arnold, MD, M.Ed.
Originally aired on October 8, 2008
- Speaker indicated the following: Adivsory Board for Abbott & Shire, Speakers Bureau for Shire, Novartis, McNeil, a Contract Recipient for Neuropharm and a Consultant for Organon & Neuropharm. *All planning committee members'/faculty/faculty identified conflicts of interest pertaining to this activity were resolved prior to the activity.
Commercial support: None
- "Lessons about ADHD from the NIMH MTA Study: Good News and Bad News after 8 Years"
High Speed (Broadband)
Peter S. Jensen, MD
Originally aired on August 6, 2008
- Speaker indicated the following: Speakers Bureau for Jassen-Orthoand Shire, Inc. and a Consultant for Shire, Inc. *All planning committee members'/faculty/faculty identified conflicts of interest pertaining to this activity were resolved prior to the activity.
Commercial support: None
- "Pediatric Obsessive Compulsive Disorder, Current Evidence about the Treatment of Pediatric Bipolar Disorder & Does Therapy Help?"
High Speed (Broadband)
Elana Harris, MD, PhD; Robert Kowatch, MD, PhD; Segio Delgado, MD
Originally aired on May 14, 2008
- Speaker indicated the following: Speakers Bureau for McNeil *All planning committee members'/faculty/faculty identified conflicts of interest pertaining to this activity were resolved prior to the activity.
Commercial support: Astra Zenca
- "Update on Attention Deficit Hyperactivity Disorder (ADHD) in Children and Adolescents"
High Speed (Broadband)
Laurence Greenhill, MD
Originally aired on April 9, 2008
- Speaker indicated the following: Consultant for Johnson&Johnson, Pfizer and recieves Grant Research Support from Otsika. *All planning committee members'/faculty/faculty identified conflicts of interest pertaining to this activity were resolved prior to the activity.
Commercial support: AstraZenca
- "The Assesment and Treatment of Juvenilee Schizophrenia"
High Speed (Broadband)
Robert L. Findling, MD
Originally aired on March 12, 2008
- Speaker indicated the following: Speakers Bureau for Johnson & Johnson and Shire, Inc. Is a consultant for Abbott, AstraZenca, Bristol-Myers Squibb, Cypress Biosciences, Forest, GlaxoSmith Kline, Johnson & Johnson, Lilly, New River, Novartis, Organon, Otsuka, Pfizer, Sanofi-Aventis, Sepracore,Shire, Inc, Solvay, Supernus Pharmaceuticals and Wyeth. Has grant/research support from Abbott, AstraZenca, Bristol-Myers Squibb, Forest, GlaxoSmith Kline, Johnson & Johnson, Lilly, New River, Otsuka, Pfizer, Shire and Wyeth *All planning committee members'/faculty/faculty identified conflicts of interest pertaining to this activity were resolved prior to the activity.
Commercial support: AstraZenca
- "The Psychiatrist's Guide to Medical Issues of Patients with Anorexia Nervosa"
High Speed (Broadband)
Child Psychiatry Grand Rounds
Laurie Mitan, MD
Originally aired on February 13, 2008
- Planning committee members/faculty were determined to have no conflicts of interest pertaining to this activity.
Commercial support: AstraZenca
- "Child Psychiatry Grand Rounds"
High Speed (Broadband)
Child Psychiatry Grand Rounds
Pamela Campbell, MD
Originally aired on January 9, 2008
- Planning committee members/faculty were determined to have no conflicts of interest pertaining to this activity.
Commercial support: AstraZenca
2007 Webcasts
- "Use of Metformin to Counteract Weight Gain from the Atypical Antipsychotics"
High Speed (Broadband)
Child Psychiatry Grand Rounds
Elizabeth Cottingham, MD
Originally aired on December 12, 2007
Speaker indicated the following: has a patent with BTG, Int. *All planning committee members'/faculty/faculty identified conflicts of interest pertaining to this activity were resolved prior to the activity.
Commercial support: AstraZenca
- "Adolescence: A Period of Vulnerabilities and Opportunities"
High Speed (Broadband)
Child Psychiatry Grand Rounds
Ronald Dahl, MD
Originally aired on October 10, 2007
Planning committee members/faculty were determined to have no conflicts of interest pertaining to this activity.
Commercial support: AstraZenca
- "The Treatment for Adolescents with Depression Study (TADS): Implications for Clinical Practice"
High Speed (Broadband)
Child Psychiatry Grand Rounds
Christopher Kratochvil, MD
Originally aired on September 12, 2007
Speaker indicated the following: Consultant for Eli Lilly & Abott, recieves Grant Research Support from Eli Lilly, Shire, Cephalon, Abott and receives DSMB from AstraZenca & Pfizer. *All planning committee members'/faculty/faculty identified conflicts of interest pertaining to this activity were resolved prior to the activity.
Commercial support: AstraZenca
- "A Gastrointestinal, Perceptual, or Emotional Disorder?"
High Speed (Broadband)
Child Psychiatry Grand Rounds
John V Campo, MD
Originally aired on June 13, 2007
- Planning committee members/faculty were determined to have no conflicts of interest pertaining to this activity.
Commercial support: AstraZenca
- "Evaluating Children at Risk for Developing Bipolar Disorder"
High Speed (Broadband)
Child Psychiatry Grand Rounds
Manpreet K Singh, MD
Originally aired on May 9, 2007
- Planning committee members/faculty were determined to have no conflicts of interest pertaining to this activity.
Commercial support: AstraZenca
- "New Research in Adolescents With Substance Use Disorders and Psychiatric Comorbidity"
High Speed (Broadband)
Child Psychiatry Grand Rounds
Paula Riggs, MD
Originally aired on April 11, 2007
- Planning committee members/faculty were determined to have no conflicts of interest pertaining to this activity.
Commercial support: AstraZenca
- "Bipolar Disorder in Children and Adolescents - Phenomenology and Course"
High Speed (Broadband)
Child Psychiatry Grand Rounds
Boris Birmaher, MD
Originally aired on March 14, 2007
- Planning committee members/faculty were determined to have no conflicts of interest pertaining to this activity.
Commercial support: AstraZenca
- "Pediatric Sleep Disorders"
High Speed (Broadband)
Child Psychiatry Grand Rounds
Kelly C. Byars, PsyD, CBSM
Originally aired on February 14, 2007
- Planning committee members/faculty were determined to have no conflicts of interest pertaining to this activity.
Commercial support: AstraZenca
- "Metabolic Risks of Second-Generation Antipsychotics"
High Speed (Broadband)
Child Psychiatry Grand Rounds
Christoph Correll, MD
Originally aired on January 10, 2007
- Planning committee members/faculty were determined to have no conflicts of interest pertaining to this activity.
Commercial support: AstraZenca
- "Psychopharmacology of Autism and Related Disorders"
High Speed (Broadband)
Child Psychiatry Grand Rounds
David J. Posey, MD, MS
Originally aired on December 13, 2006
- Planning committee members/faculty were determined to have no conflicts of interest pertaining to this activity.
Commercial support: AstraZenca
|
